85 related articles for article (PubMed ID: 38665259)
21. Pathophysiology of Hypercalcemia.
Goltzman D
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):591-607. PubMed ID: 34774236
[TBL] [Abstract][Full Text] [Related]
22. Hypercalcemia due to CYP24A1 mutations: a systematic descriptive review.
Cappellani D; Brancatella A; Morganti R; Borsari S; Baldinotti F; Caligo MA; Kaufmann M; Jones G; Marcocci C; Cetani F
Eur J Endocrinol; 2021 Dec; 186(2):137-149. PubMed ID: 34735369
[TBL] [Abstract][Full Text] [Related]
23. Differential diagnosis of vitamin D-related hypercalcemia using serum vitamin D metabolite profiling.
Kaufmann M; Schlingmann KP; Berezin L; Molin A; Sheftel J; Vig M; Gallagher JC; Nagata A; Masoud SS; Sakamoto R; Nagasawa K; Uesugi M; Kottler ML; Konrad M; Jones G
J Bone Miner Res; 2021 Jul; 36(7):1340-1350. PubMed ID: 33856702
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of common vitamin D supplementation in primary hyperparathyroidism and coexistent vitamin D deficiency and insufficiency: a systematic review and meta-analysis.
Song A; Zhao H; Yang Y; Liu S; Nie M; Wang O; Xing X
J Endocrinol Invest; 2021 Aug; 44(8):1667-1677. PubMed ID: 33453021
[TBL] [Abstract][Full Text] [Related]
25. Do the Heterozygous Carriers of a CYP24A1 Mutation Display a Different Biochemical Phenotype Than Wild Types?
Brancatella A; Cappellani D; Kaufmann M; Borsari S; Piaggi P; Baldinotti F; Caligo MA; Jones G; Marcocci C; Cetani F
J Clin Endocrinol Metab; 2021 Mar; 106(3):708-717. PubMed ID: 33249478
[TBL] [Abstract][Full Text] [Related]
26. Therapy-Resistant Hypercalcemia in a Patient with Inactivating CYP24A1 Mutation and Recurrent Nephrolithiasis: Beware of Concomitant Hyperparathyroidism.
David K; Khalil R; Hannon H; Evenepoel P; Decallonne B
Calcif Tissue Int; 2020 Nov; 107(5):524-528. PubMed ID: 32743688
[TBL] [Abstract][Full Text] [Related]
27. CYP24A1 and SLC34A1 genetic defects associated with idiopathic infantile hypercalcemia: from genotype to phenotype.
De Paolis E; Scaglione GL; De Bonis M; Minucci A; Capoluongo E
Clin Chem Lab Med; 2019 Oct; 57(11):1650-1667. PubMed ID: 31188746
[TBL] [Abstract][Full Text] [Related]
28. Hereditary Hypercalcemia Caused by a Homozygous Pathogenic Variant in the
Cappellani D; Brancatella A; Kaufmann M; Minucci A; Vignali E; Canale D; De Paolis E; Capoluongo E; Cetani F; Jones G; Marcocci C
Case Rep Endocrinol; 2019; 2019():4982621. PubMed ID: 31089432
[TBL] [Abstract][Full Text] [Related]
29. Reference values for 24,25-dihydroxyvitamin D and the 25-hydroxyvitamin D/24,25-dihydroxyvitamin D ratio.
Dirks NF; Ackermans MT; de Jonge R; Heijboer AC
Clin Chem Lab Med; 2019 Sep; 57(10):e259-e261. PubMed ID: 30903750
[No Abstract] [Full Text] [Related]
30. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment.
Mizobuchi M; Ogata H; Koiwa F
Ther Apher Dial; 2019 Aug; 23(4):309-318. PubMed ID: 30411503
[TBL] [Abstract][Full Text] [Related]
31. Vitamin D measurement and effect on outcome in a cohort of patients with heart failure.
Saponaro F; Saba A; Frascarelli S; Frontera C; Clerico A; Scalese M; Sessa MR; Cetani F; Borsari S; Pardi E; Marvelli A; Marcocci C; Passino C; Zucchi R
Endocr Connect; 2018 Sep; 7(9):957-964. PubMed ID: 30300540
[TBL] [Abstract][Full Text] [Related]
32. Primary Hyperparathyroidism.
Bilezikian JP
J Clin Endocrinol Metab; 2018 Nov; 103(11):3993-4004. PubMed ID: 30060226
[TBL] [Abstract][Full Text] [Related]
33. Genetic Diseases of Vitamin D Metabolizing Enzymes.
Jones G; Kottler ML; Schlingmann KP
Endocrinol Metab Clin North Am; 2017 Dec; 46(4):1095-1117. PubMed ID: 29080636
[TBL] [Abstract][Full Text] [Related]
34. Improved Screening Test for Idiopathic Infantile Hypercalcemia Confirms Residual Levels of Serum 24,25-(OH)
Kaufmann M; Morse N; Molloy BJ; Cooper DP; Schlingmann KP; Molin A; Kottler ML; Gallagher JC; Armas L; Jones G
J Bone Miner Res; 2017 Jul; 32(7):1589-1596. PubMed ID: 28304097
[TBL] [Abstract][Full Text] [Related]
35. CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations.
Carpenter TO
J Steroid Biochem Mol Biol; 2017 Oct; 173():337-340. PubMed ID: 28093352
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.
Tebben PJ; Singh RJ; Kumar R
Endocr Rev; 2016 Oct; 37(5):521-547. PubMed ID: 27588937
[TBL] [Abstract][Full Text] [Related]
37. Hyperparathyroidism complicating CYP 24A1 mutations.
Loyer C; Leroy C; Molin A; Odou MF; Huglo D; Lion G; Ernst O; Hoffmann M; Porchet N; Carnaille B; Pattou F; Kottler ML; Vantyghem MC
Ann Endocrinol (Paris); 2016 Oct; 77(5):615-619. PubMed ID: 27378451
[TBL] [Abstract][Full Text] [Related]
38. Idiopathic infantile hypercalcemia: case report and review of the literature.
Marks BE; Doyle DA
J Pediatr Endocrinol Metab; 2016 Feb; 29(2):127-32. PubMed ID: 26501157
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of hypercalcaemia associated with a CYP24A1 mutation with fluconazole.
Sayers J; Hynes AM; Srivastava S; Dowen F; Quinton R; Datta HK; Sayer JA
Clin Kidney J; 2015 Aug; 8(4):453-5. PubMed ID: 26251716
[TBL] [Abstract][Full Text] [Related]
40. Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: A cross-sectional study.
Cools M; Goemaere S; Baetens D; Raes A; Desloovere A; Kaufman JM; De Schepper J; Jans I; Vanderschueren D; Billen J; De Baere E; Fiers T; Bouillon R
Bone; 2015 Dec; 81():89-96. PubMed ID: 26117226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
